{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:05:27Z","timestamp":1791518727566,"version":"4.3.4"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T00:00:00Z","timestamp":1489968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0174005","type":"journal-article","created":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T14:05:12Z","timestamp":1490018712000},"page":"e0174005","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":34,"title":["Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2833-6337","authenticated-orcid":true,"given":"Harald","family":"Hegen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Auer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bsteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Di Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Plavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janette","family":"Walde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Deisenhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,3,20]]},"reference":[{"key":"ref1","first-page":"899","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"CH Polman","year":"2006"},{"key":"ref2","first-page":"425","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"CS Tan","year":"2010"},{"key":"ref3","first-page":"1870","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"G Bloomgren","year":"2012"},{"key":"ref4","first-page":"1533","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"T Olsson","year":"2013"},{"key":"ref5","first-page":"1736","article-title":"Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort","volume":"78","author":"AK Trampe","year":"2012"},{"key":"ref6","first-page":"742","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1","volume":"70","author":"C Bozic","year":"2011"},{"key":"ref7","article-title":"JC-virus seroconversion in multiple sclerosis patients receiving natalizumab","author":"O Outteryck","year":"2013"},{"key":"ref8","first-page":"802","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"T Plavina","year":"2014"},{"key":"ref9","first-page":"295","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"L Gorelik","year":"2010"},{"key":"ref10","first-page":"61","article-title":"JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study","volume":"360","author":"R Alroughani","year":"2016"},{"key":"ref11","first-page":"16","article-title":"Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain","volume":"365","author":"Y Aladro","year":"2016"},{"key":"ref12","first-page":"1079","article-title":"High cumulative JC virus seroconversion rate during long-term use of natalizumab","volume":"23","author":"A Vennegoor","year":"2016"},{"key":"ref13","first-page":"391","article-title":"Anti-JC virus seroprevalence in a Finnish MS cohort","volume":"133","author":"M Kolasa","year":"2016"},{"key":"ref14","first-page":"e195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"N Schwab","year":"2016"},{"key":"ref15","first-page":"292","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"CH Polman","year":"2011"},{"key":"ref16","first-page":"1157","article-title":"Differential diagnosis of suspected multiple sclerosis: a consensus approach","volume":"14","author":"DH Miller","year":"2008"},{"key":"ref17","first-page":"907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"FD Lublin","year":"1996"},{"key":"ref18","first-page":"e29","article-title":"IV immunoglobulin confounds JC virus antibody serostatus determination","volume":"1","author":"I Kister","year":"2014"},{"key":"ref19","first-page":"141","article-title":"A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"P Lee","year":"2013"},{"key":"ref20","first-page":"65","article-title":"Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma","volume":"53","author":"T Plavina","year":"2012"},{"key":"ref21","unstructured":"Tysabri. Product information. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/wwwemaeuropaeu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000603\/WC500044686pdf\" xlink:type=\"simple\">http:\/\/wwwemaeuropaeu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000603\/WC500044686pdf<\/ext-link>. Accessed 23 Jan 2017."},{"key":"ref22","first-page":"1833","article-title":"Anti-JC virus antibody titres increase over time with natalizumab treatment","volume":"21","author":"J Raffel","year":"2015"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0174005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T09:30:45Z","timestamp":1540027845000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0174005"}},"subtitle":[],"editor":[{"given":"Klemens","family":"Ruprecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,20]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0174005","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,20]]}}}